secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001789769-23-000067
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q1 net loss $57.1M; cash $223.9M; ITIL-306 phase 1 expected in 2H 2023
--------------------------------------------------------------------------------

- Net loss of $57.1M ($0.44 per share) vs $54.1M ($0.42) in Q1 2022; restructuring charges of $24.6M.
- Cash, equivalents, restricted cash and marketable securities $223.9M at Mar 31, 2023, down from $260.9M at Dec 31, 2022; runway beyond 2026.
- ITIL-306 phase 1 study in UK anticipated to initiate in 2H 2023 after MHRA CTA clearance; initial data expected in 2024.
- R&D expenses fell to $20.7M from $39.2M YoY; quarterly cash burn expected <$10M from 2H 2023 through end of 2024.
- Consolidating R&D to UK; pursuing lease or sale of Tarzana, CA manufacturing facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000067/0001789769-23-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976923000067/til-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001789769-23-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer